Lupin is a biopharma company.
Lupin has received tentative approval from the U.S. FDA for Apixaban Oral Suspension 1.25 mg/mL, an oral liquid formulation of the active ingredient in Eliquis that offers an alternative administration option for adults requiring anticoagulation therapy.
Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP
Latest PR Newswire FDA coverage of Lupin Announces Approval from U.S. FDA for Pitolisant Tablets
Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States
Lupin seeds US spinout with cash, clinical-stage cancer assets.
Lupin Receives Tentative Approval from U.S. FDA for Enzalutamide Tablets Global pharmaceutical leader Lupin Limited (Lupin) (B